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Beginning July 8th the Iowa 
Department of Public Health 
Immunization Program will be 
presenting regional Vaccine 
University classes.  The summer 
Vaccine University is offering three 
classes:   
Vaccine 101— a basic course in 
the immunization schedule 
including application 
of the immunization 
schedule in real live 
scenarios;  
Vaccine Storage & 
Handling— back by 
popular demand, this 
class will be a repeat 
of the class offered in 
November focusing 
on how to protect 
your vaccine supply, 
proper temperatures, 
storage and handling, 
and vaccine 
emergency response 
plan;  
IRIS Training— a 
basic introduction to 
the IRIS program 
and hands on work 
within the program 
to learn about 
vaccine 
accountability, 
vaccine ordering, 
inventory, and 
user/preference lists.  
There is no fee for the classes and 
CEUs will be offered for nurses and 
CMAs.   
Space is limited so sign up early.  
For additional information on 
classes, or to register, visit: 
http://www.idph.state.ia.us/a
dper/immunization.asp  
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On May 14, 2008, the Iowa Im-
munization Advisory Committee 
met to review proposed changes 
to Iowa Administrative Code 
641.7:  Immunization and Im-
munization Education: Persons 
Attending Elementary or Secon-
dary Schools, Licensed Child 
Care Centers or Institutions of 
Higher Education. Proposed 
changes to Chapter 7 include:  
• Clarification of the definition 
for “certified medical assis-
tant” and add a definition for 
“student.” The amendments 
further explain the use of 
medical and religious ex-
emptions.   
• Guidelines are provided on 
how to complete the Certifi-
cate of Immunization and 
Provisional Certificate of Im-
munization.   
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• Detail as to who is required 
to sign a Provisional Certifi-
cate of Immunization is in-
cluded.  This amendment 
also removes the require-
ment of a school or child 
care to offer a meeting to 
parents prior to a child’s 
provisional enrolment expi-
ration and replaces it with 
the requirement for written 
explanation of rules regard-
ing provisional enrollment. 
• Amendments clarify the 
need for a second Provi-
sional Certificate of Immu-
nization in the circum-
stance that a provisional 
certificate expires due to a 
minimum interval.   
• The description of who can 
provide immunization re-
cord information to whom 
has been clarified.   
• Finally, the immunization 
requirements are updated to 
more accurately reflect the 
recommendations of the Ad-
visory Committee on Immu-
nization Practices (ACIP) as 
well as the inclusion of re-
quired immunization for in-
vasive pneumococcal disease 
for children enrolling in li-
censed child care centers 
(per HF245).   
More information regarding the 
proposed changes to Chapter 7, 
as well as the rule making proc-
ess will be available soon.  To 
review Chapter 7 as it stands 
now visit: 
http://www.legis.state.ia.us/Rul
es/Current/iac/641iac/6417/641
7.pdf 
Questions should be directed to 
Bridget Konz, 800-831-6293, ext 
7 or bkonz@idph.state.ia.us. 
 
A fter an adult has either been infected with or exposed to pertussis, is vaccination with Tdap recommended, and if so when? Yes. Adults who have a history of pertussis 
disease generally should receive Tdap according to the routine recommen-
dation. In the U.S., two Tdap products are licensed for use. Adacel® (sanofi 
pasteur) is licensed for use in persons age 11–64 years, and Boostrix® 
(GlaxoSmithKline), is licensed for persons age 10–18 years. This practice 
is recommended because the duration of protection induced by pertussis 
disease is unknown (waning might begin as early as 7 years after infection) 
and because diagnosis of pertussis can be difficult to confirm, particularly 
with tests other than culture for B. pertussis. Administering pertussis vac-
cine to persons with a history of pertussis presents no theoretical risk. For details, visit CDC’s pub-
lished recommendations on this topic at www.cdc.gov/mmwr/PDF/rr/rr5517.pdf (pages 24–25). 
 
C an a booster dose of Tdap be given to persons age 65 years and older? No brand of Tdap is approved by FDA for persons age 65 years and older. ACIP does not recommend off-label use of Tdap for this age group. However, a clinician may choose to administer Tdap to a 
person age 65 years or older if both patient and clinician agree that the benefit of Tdap outweighs the 
risk of a local adverse event. 
Source:  Immunization Action Coalition (Vaccinate Women Volume 7- Number, June 2008) 
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 Tiered Ordering Frequency for VFC 
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T ransitioning to McKesson for centralized vaccine distribution has 
required providers to implement 
a Tiered Ordering Frequency 
(TOF).  TOF is a provider 
ordering schedule identifying 
the number of orders providers 
should place each year.   
CDC established each provider’s 
TOF based on annual historic 
doses distributed reports.  Based 
on those reports, providers were 
classified in TOFs of monthly, 
every other month, or quarterly. 
Nonviable Vaccine?  
Expired or wasted vaccines must be returned to McKesson.  Do not send them to the Iowa Department 
of Public Health as we do not have the facility to store or ship these vaccines.  To return nonviable vac-
cine follow these steps:  
1. Complete the Nonviable Return Form (found on our web page: 
http://www.idph.state.ia.us/adper/vaccines_for_children.asp). State the reason vaccine is nonvi-
able – see return code reasons listed below AND document if these vaccines were transferred to 
you from another Iowa VFC clinic by listing the original 
clinic name and VFC PIN. 
2. Label the vaccine “nonviable” to avoid unintentional use 
and write “Non-viable Vaccine Enclosed” on the box. 
3. With the completed form: a) make a copy for your re-
cords, b) fax a copy to the Immunization Program at       
1-800-831-6292, and c) include the original with the    
returned vaccine.   
4. Pack the vaccine to protect it from breakage.  Cold packs 
are not necessary, as nonviable doses will never be        
administered.  
Wasted and expired vaccine should be returned using the McKesson insulated containers and the sup-
plied return postage label.  If you do not have a McKesson shipping box available, pack the nonviable 
vaccine into a box and return it to: McKesson Specialty Distribution, 4853 Crumpler Road, Memphis, 
Tennessee 38141.  It is not necessary to ship vaccine by priority mail.  
If you have additional questions, please contact Janean Iddings at 800-831-6293, ext 5.  
The goal of TOF is to balance 
shipping costs with inventory 
and potential wastage costs to 
lower the total cost of 
distribution.   
TOF guidelines also serve as a 
means to decrease manual 
ordering processes associated 
with vaccine orders.  
Adherence to your TOF is best 
accomplished by the following 
steps:  
1. Take a complete inventory 
of vaccine on hand.        
2. Look ahead to what is 
planned (i.e. flu clinics, back to 
school). 
3. Review previous doses 
administered reports for 
indications of seasonal use. 
4. Place the order for ALL 
vaccines that will be needed in 
the TOF timeframe. 
If you do not know your TOF, 
or have questions regarding 
doses administered data, 
please contact Janean Iddings 
at 800-831-6293, ext 5. 
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In 2005, two tetanus toxoid, re-
duced diphtheria toxoid, and 
acellular pertussis (Tdap) vac-
cines were licensed and recom-
mended for use in adults and 
adolescents in the United States. 
 Both Tdap vaccines are licensed 
for single-dose use to add pro-
tection against pertussis and to 
replace the next dose of tetanus 
and diphtheria toxoids vaccine 
(Td) for all adults and adoles-
cents, including women of child-
bearing age. However, the safety 
and efficacy of Tdap in pregnant 
women has not been demon-
strated.  
The ACIP recommends Tdap for 
postpartum women at delivery 
Epidemiology and Prevention of Vaccine-Preventable Diseases 2008: This four-part self-
study series provides the most current information available in the constantly changing field of im-
munization. Together, the four sessions offer a comprehensive overview on immunization today.   
• Session ONE discusses principles and general recommendations on vaccination.  
• Sessions TWO, THREE and FOUR discuss specific vaccine-preventable diseases and their respec-
tive vaccines.  
Each of the four sessions is three hours in duration. Continuing Education credits will be provided. 
This self-study program is offered free of charge in DVD and Web-on-demand formats. For more in-
formation on how to order the DVD or access the Web-based version go to 
www.cdc.gov/vaccines/ed/epivac/default.htm 
Upcoming Satellite Broadcast; Immunization Update 2008. August 28, 2008. This live sat-
ellite broadcast and Webcast will provide up-to-date information on the rapidly changing field of im-
munization.  Anticipated topics include influenza and zoster vaccines, recently approved vaccines, 
and updates on vaccine supplies and vaccine safety.   
The 2.5-hour broadcast will occur live from 9:00 to 11:30 am and will be re-broadcast that day from 
12:00 noon to 2:30 pm (Eastern Time). Both broadcasts will feature a live question-and-answer ses-
sion in which participants nationwide can interact with the course instructors via toll-free telephone 
lines. Continuing  education credits will be provided.  For further information about viewing either 
the satellite broadcast or accessing the Webcast,  go  to www.cdc.gov/vaccines/ed after June 15.   
before leaving the hospital or 
birthing center to boost their 
protection for pertussis and to 
reduce the risk of transmitting 
pertussis to the infant, if they 
have not previously had a dose 
of Tdap.  
Some pregnant women due for a 
Td booster will have sufficient 
tetanus and diphtheria protec-
tion to allow the Td during preg-
nancy to be deferred to substi-
tute Tdap at delivery. However, 
until additional information is 
available, the ACIP has reaf-
firmed its current recom-
mendation to use Td 
(rather than Tdap) in preg-
nant women if they are due 
for vaccination to prevent ma-
CDC Offers Immunization Training  
ACIP Recommendations on Prevention of Pertussis, Tetanus, and Diphtheria Among 
Pregnant and Postpartum Women and Their Infants 
ternal or neonatal tetanus, or 
to prevent diphtheria and do 
not have sufficient protection 
until delivery.  
The ACIP continues to encour-
age adults and adolescents, 
who might come in contact 
with an infant (e.g., fathers, 
grandparents, child care pro-
viders) to have the Tdap dose 
before the usual 10 years be-
tween Td boosters, to decrease 
their chance of getting pertus-
sis and transmitting it to the 
infant. The recommendations 
released in the MMWR further 
addresses these issues: 
http://www.cdc.gov/mmwr/pr
eview/mmwrhtml/rr57e0514a
1.htm 
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VAERS Reporting 
The Vaccine Adverse Event 
Reporting System (VAERS) is 
a national vaccine safety sur-
veillance program co-
sponsored by the Centers for 
Disease Control and Preven-
tion (CDC) and the Food and 
Drug Administration (FDA). 
VAERS collects and analyzes 
information from reports of 
adverse events following im-
munization.  
Since 1990, VAERS has re-
ceived over 123,000 reports, 
most of which describe mild 
side effects such as fever. Very 
rarely, people experience seri-
ous adverse events following 
immunization. By monitoring 
such events, VAERS can help 
to identify important new 
safety concerns. 
Who can file a VAERS re-
port? Anyone can submit a 
VAERS report. Most reports 
are sent in by vaccine manu-
facturers (42%) and health 
care providers (30%). The rest 
are submitted by state immu-
nization programs (12%), vac-
cine recipients or their par-
ent/guardians (7%), and other 
sources (9%). 
What adverse events 
should be reported? 
VAERS encourages the report-
ing of any clinically significant 
adverse event that occurs after 
the administration of any vac-
cine licensed in the United 
States. Report such events 
even if you are unsure whether 
a vaccine caused them.  
The National Childhood Vac-
cine Injury Act (NCVIA) re-
quires health care providers to 
report: 
• Any event listed by the 
vaccine manufacturer as a 
contraindication to subse-
quent doses of the vaccine. 
•  Any event listed in the Re-
portable Events Table that 
occurs within the specified 
time period after vaccina-
tion. 
A copy of the Reportable 
Events Table can be found in 
the CDC Pink Book or ob-
tained by calling VAERS at 1-
800-822-7967 or by 
downloading it from 
http://vaers.hhs.gov/pubs.ht
m. 
Filing a VAERS report: 
Use a VAERS report form to 
report any adverse event. 
You can get pre-addressed 
postage paid report forms by 
calling VAERS at 1-800-822-
7967, or download a printable 
copy of the VAERS form from 
the following Internet sites: 
http://vaers.hhs.gov/ 
www.fda.gov/cber/vaers/vaer
s.htm 
www.cdc.gov/vaccines/ 
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Instructions are included with 
the form. You may use a photo-
copy of the VAERS form to sub-
mit a report. For more informa-
tion:  
• Send e-mail inquiries to 
info@vaers.org 
• Visit the VAERS Web site at: 
http://vaers.hhs.gov  
• Call the toll-free VAERS in-
formation line at (800) 822-
7967 
• Fax inquiries to the toll-free 
information fax line at (877) 
721-0366 
For information regarding 
VAERS at the Iowa Immuniza-
tion Program, contact Terri 
Thornton at 1-800-831-6293,   
ext 2 
Do you want to have the Immunization Update Newsletter sent to you directly? Do you know someone who would?  
Send your name and mailing address to Bkonz@idph.state.ia.us and we will sign you up—it’s as easy as that!  The Immunization Update is 
also available on our Web page at: www.idph.state.ia.us/adper/immunization.asp It’s a great way to send the Newsletter on to others in your 
facility or community. 
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